初诊2型糖尿病胰岛素强化治疗后的胰岛功能变化分析  

The Comparison of the β-cell Function between Continuous Subcutaneous Insulin Infusion and Multiple Daily Infusion on Newly Diagnosed Type 2 Diabetic Patients Given Short-term Intensive Therapy

作　　者：冯佳庆[1] 王茜[1] 刘超[1] 沈备[1] 

机构地区：[1]南京医科大学第一附属医院内分泌科,江苏南京210029

出　　处：《江苏大学学报（医学版）》2005年第5期409-411,共3页Journal of Jiangsu University：Medicine Edition

摘　　要：目的:探讨短期胰岛素泵强化治疗(CSII)和胰岛素多点皮下注射(MD I)强化治疗初诊2型糖尿病患者胰岛β细胞功能改变。方法:38例空腹血糖≥7.0 mmol/L的初诊2型糖尿病患者随机分为CSII组和MD I组,CSII组共24人,MD I组共14人,进行一个月强化治疗,以末梢空腹血糖<6.1 mmol/L和餐后2 h血糖<7.8 mmol/L为血糖控制目标。根据血糖调整胰岛素用量,比较两组治疗前后的口服葡萄糖耐量试验胰岛素和C肽曲线下面积、Hom a胰岛功能(Hom aβ)和抵抗指数(Hom a R I)。结果:治疗前后,两组间的胰岛素和C肽曲线下面积、HOMA胰岛功能和抵抗指数无明显的统计学意义。除Hom a R I外,同组内其他上述指标在治疗前后有明显的统计学差别。结论:胰岛素泵强化治疗和胰岛素多点注射强化治疗都可以使初诊2型糖尿病患者的胰岛细胞功能得到同样程度的改善。Objective： To investigate the comparison of the β-cell function between continuous subcutaneous insulin infusion （CSII） and multiple daily infusion （MDI） on newly diagnosed type 2 diabetic patients. Methods： Tweenty four newly diagnosed type 2 diabetic patients with fasting plasma glucose ≥7.0 mmol/L were treated with CSII for 1 month and 14 patients were treated with MDI for 1 month. Oral glucose tolerance test（OGTT） was performed before and after in two groups. The target of glyeemie control were fasting blood glucose（FBG） 〈6.1 mmol/L and postprandial plasma glucose （PBG） 〈7.8 mmol/L. The Homa β, Homa IR, and area under the curve of insulin and C-peptide （AUC） during OGTT were compared between the CSII group and the MDI group. Results： After 1 month＇s intensive treatment, there were no differences in MBI, AUCCSII,AUCMDI, Homaβand Homa IR between the two groups before and after treatment. The AUC representing the recovery of β-cell function was much greater in two group before and after treatment. Conclusion： The same excellent improvement of β-cell can be induced by short-term CSII and MDI in newly diagnosed diabetes.

关 键 词：初诊2型糖尿病 口服葡萄糖耐量试验 强化治疗 

分 类 号：R587.1[医药卫生—内分泌]